Overview
Prostate Biopsy (2026)
Coding & Documentation Overview
Beginning in 2026, prostate biopsy coding is driven by approach (transrectal vs transperineal),
guidance (ultrasound only vs MRI–ultrasound fusion vs in-bore CT/MRI), and the
sampling strategy (systematic, targeted only, or systematic + targeted).
Code selection is based on targets (regions of interest)—not the number of cores.
Most common clinical indications
- Elevated/rising PSA
- Abnormal DRE
- Suspicious prostate MRI (e.g., PI-RADS 3–5)
- Repeat biopsy or active surveillance
Documentation drivers (prevent denials)
- Approach: transrectal vs transperineal
- Guidance: US only vs MRI–US fusion vs in-bore CT/MRI
- Sampling strategy: systematic only vs targeted only vs systematic + targeted
- Targeted lesion count: number of distinct targeted lesions (supports add-on units)
- Anesthesia type and setting when relevant to payer policy
- Specimen chain: labeling, container count, transport (reduces downstream disputes)
Coding patterns (high-level)
- CPT®: select by approach + guidance + strategy (systematic vs targeted vs combined)
- Add-on: 55715 is per additional targeted lesion (not per core)
- ICD-10: align diagnosis to documented indication (PSA, imaging abnormality, cancer hx, etc.)
Common denial causes
- “Fusion” billed but documentation reads like cognitive targeting
- Missing targeted lesion count (or confusing targets with cores)
- Mismatch between physician op note and facility record (approach/guidance not aligned)
- In-bore guidance not clearly supported in radiology/facility documentation
Top Questions (quick answers)
What drives CPT selection for prostate biopsy in 2026?
CPT selection is driven by approach, guidance modality,
and whether biopsy is systematic, targeted only, or systematic + targeted.
Targets—not cores—drive coding.
Does cognitive targeting count as MRI–ultrasound fusion guidance?
No. Cognitive targeting (reviewing MRI without fusion technology) does not meet CPT criteria for MRI–ultrasound fusion guidance. Documentation should support use of a fusion platform/workstation when fusion is billed.
How do I bill additional targeted lesions?
Report 55715 per additional targeted lesion beyond the first, when performed with eligible primary procedures. Units reflect additional lesions, not additional cores.
What should always be documented to support fusion or in-bore workflows?
Document the guidance modality used and evidence of the workflow (fusion platform/workstation for fusion; radiology/facility documentation for in-bore CT/MRI), plus the number of distinct targeted lesions.
How should I document the indication for biopsy?
Clearly document why biopsy is required (elevated/rising PSA, abnormal DRE, suspicious MRI such as PI-RADS 3–5, repeat biopsy, active surveillance) and the clinical context supporting medical necessity.
What is the difference between systematic and targeted biopsy for coding?
Systematic biopsy refers to template-based sampling; targeted biopsy refers to sampling discrete ROI lesions. Code selection depends on whether systematic only, targeted only, or both were performed in the same session.
How do I document targets correctly?
Document the number of distinct targeted lesions (ROI count) and the targeting technology used. Do not use “cores” as the basis for code selection.
What must be true to report MRI–ultrasound fusion guidance?
The record should support use of a fusion platform/workstation. Cognitive targeting alone does not meet fusion criteria.
How do I avoid claim conflicts between physician and facility?
Ensure both records clearly state the same approach (TR vs TP), guidance modality, sampling strategy, and targeted lesion count. Payers often deny when the records tell different stories.
Example A — Transperineal systematic + MRI–US fusion targeted biopsy (multiple targets)
Clinical: Elevated PSA and MRI with two suspicious lesions; transperineal approach with systematic sampling plus fusion-guided targeted sampling of two distinct lesions.
Code(s): Primary fusion/systematic+targeted code (by approach) + 55715 x 1 for the additional targeted lesion beyond the first (when eligible).
Dx: R97.20 and/or imaging abnormality code supported by documentation.
Example B — Targeted-only fusion biopsy
Clinical: Prior negative systematic biopsy; repeat biopsy performed as targeted-only sampling of one MRI ROI lesion using MRI–US fusion platform (no systematic sampling).
Code(s): Targeted-only fusion code by approach; no add-on unless additional lesions were targeted.
Dx: Documented indication (e.g., elevated PSA, abnormal imaging).
Always document
- Medical necessity: PSA trend, DRE findings, MRI PI-RADS, repeat biopsy rationale, or active surveillance rationale
- Approach: transrectal vs transperineal
- Guidance: ultrasound only vs MRI–US fusion vs in-bore CT/MRI
- Sampling strategy: systematic only vs targeted only vs systematic + targeted
- Targeted lesion count: number of distinct ROI lesions targeted
- Anesthesia type and setting when relevant
- Specimen handling chain: labeling, container count, transport
Fusion / in-bore support language
- Fusion: document that MRI–US fusion was performed using a fusion platform/workstation (not cognitive targeting)
- In-bore: document imaging performed during the procedure with in-bore CT/MRI guidance; include radiology/facility timestamps when available
- Targets vs cores confusion: explicitly document targeted lesion count; do not rely on “12 cores” language to describe targets.
- Fusion not supported: include evidence of fusion platform/workstation use; avoid language that reads like cognitive targeting.
- In-bore ambiguity: ensure radiology/facility documentation supports in-bore workflow; vague documentation invites denial.
- Record mismatch: align physician op note and facility record (approach/guidance/strategy/targets).
Physician Coding
Prostate Biopsy (2026)
Physician Coding & Documentation
Select codes based on approach, guidance modality, and
sampling strategy. Add-on reporting is based on the number of additional targeted lesions.
How to choose: Select codes based on approach (TR vs TP), guidance (US only vs fusion vs in-bore),
and whether biopsy is systematic, targeted-only, or systematic + targeted. Targets—not cores—drive coding.
Transrectal approach
- 55707 – Biopsy, prostate, transrectal, ultrasound-guided (systematic/sextant; may include US-localized lesion[s])
- 55708 – Transrectal, ultrasound-guided systematic (sextant) with MRI-fusion guidance, first targeted lesion
- 55711 – Transrectal, MRI–US fusion guided, targeted lesion(s) only, first targeted lesion
Transperineal approach
- 55709 – Biopsy, prostate, transperineal, ultrasound-guided (systematic/sextant; may include US-localized lesion[s])
- 55710 – Transperineal, ultrasound-guided systematic (sextant) with MRI-fusion guidance, first targeted lesion
- 55712 – Transperineal, MRI–US fusion guided, targeted lesion(s) only, first targeted lesion
In-bore CT or MRI–guided biopsy
- 55713 – In-bore CT/MRI guided (systematic/sextant) with targeted lesion(s), first targeted lesion
- 55714 – In-bore CT/MRI guided targeted lesion(s) only, first targeted lesion
Add-on (additional targeted lesions)
- 55715 – Each additional MRI–US fusion or in-bore CT/MRI guided targeted lesion (add-on)
- May be added to: 55708, 55710, 55711, 55712, 55713, 55714
Tip: Report 55715 per additional targeted lesion beyond the first (units = additional lesions), not per core.
Pair diagnosis codes with clear indication in the documentation (e.g., elevated PSA, abnormal MRI, active surveillance).
- C61 – Malignant neoplasm of prostate
- N40.2 – Nodular prostate without lower urinary tract symptoms
- N40.3 – Nodular prostate with lower urinary tract symptoms
- R97.20 – Elevated PSA, unspecified
- R97.21 – Rising PSA following treatment for malignant neoplasm of prostate
- R93.89 – Abnormal findings on diagnostic imaging of other specified body structures
- Z85.46 – Personal history of malignant neoplasm of prostate
Tip: Document the indication explicitly so the diagnosis selection is defensible (PSA trend, PI-RADS score, surveillance status, etc.).
- Medical necessity: elevated/rising PSA, abnormal DRE, suspicious MRI (PI-RADS), repeat biopsy rationale, or active surveillance rationale
- Biopsy indication: initial vs repeat vs active surveillance
- Approach: transrectal vs transperineal
- Guidance modality: US only vs MRI–US fusion vs in-bore CT/MRI
- Sampling strategy: systematic only vs targeted only vs systematic + targeted
- Targeted lesion count: number of distinct lesions (supports add-on units)
- Fusion evidence: fusion platform/workstation documented (not cognitive targeting)
- Anesthesia: type used and setting when payer policy is sensitive
- Specimen chain: labeling, container count, transport documentation
Modifier use
- -22 may be appropriate when the procedure requires significantly more effort than usual (multiple difficult targets, complex anatomy, extended operative time). Support with specific details in the op note.
- -52 may be considered in payer-specific scenarios when service does not fully meet descriptor requirements. Support with clear documentation and payer guidance when available.
Modifier -22 example (from your content)
Scenario: MRI–US fusion transperineal biopsy with multiple targets plus systematic sampling requiring additional planning, fusion work, repeated needle repositioning, and extended operative time.
Documentation concept: “The procedure required approximately 2× usual operative time due to MRI–US fusion targeting of multiple suspicious lesions, transperineal access, and repeated needle repositioning to ensure accurate sampling of all regions of concern.”
Global period awareness
- Codes 55707–55714 carry a 0-day global.
- 55715 is an add-on (ZZZ) code and follows the global period of the primary procedure.
2026 key takeaways
- Cores do not drive coding — targets do.
- Approach + guidance + targeting determine CPT selection.
- MRI fusion requires true fusion technology (not cognitive targeting).
- 55715 units represent additional targeted lesions (not additional cores).
Facility Coding
Prostate Biopsy (2026)
Facility Coding & Documentation
Facility claims should align with the same 2026 framework used for physician coding: approach,
guidance, and targeting strategy. Clear documentation and clean charge capture are the best defense
against denials—especially for MRI-fusion and in-bore workflows.
- Site-of-service matters: office/clinic, ASC, and HOPD often follow different payment/packaging rules.
- Charge capture alignment: ensure the facility claim reflects the performed approach (TR/TP), guidance modality, and sampling strategy.
- Resource documentation: fusion platform/workstation use and in-bore imaging resource use should be supported in the facility record.
- Supplies/equipment capture: follow facility CDM and payer packaging rules for disposables and specialized equipment.
Facility ICD-10 selection should match the documented indication and align with the physician claim.
- C61 – Malignant neoplasm of prostate
- R97.20 – Elevated PSA, unspecified
- R93.89 – Abnormal diagnostic imaging finding (when supported)
- Z85.46 – Personal history of malignant neoplasm of prostate
- R97.21 – Rising PSA following treatment for malignant neoplasm of prostate
- N40.2 / N40.3 – Nodular prostate (when supported)
Facility tip: mismatched indications between facility and physician records commonly trigger payer review/denial.
To reduce denials and miscoding, ensure these elements are captured in the facility record (op note + nursing/tech documentation + device logs as applicable):
- Approach: transrectal vs transperineal (explicit language).
- Guidance modality: ultrasound only vs MRI–US fusion vs in-bore CT/MRI.
- Targeting strategy: systematic only vs targeted only vs systematic + targeted.
- Targeted lesion count: number of distinct targeted lesions (supports add-on unit logic when applicable).
- Fusion evidence (if used): fusion performed using a fusion platform/workstation (not cognitive targeting).
- In-bore evidence (if used): imaging performed during the procedure with in-bore CT/MRI guidance (include departmental documentation/timestamps when available).
- Anesthesia record: type of anesthesia, start/stop times, staffing per facility protocol.
- Specimen chain: labeling, number of containers, and transport documentation.
Why this matters: when physician and facility records conflict (e.g., fusion implied in one record but not the other), payers often default to denial or downcoding.
Charge capture tips: common misses
- Targets vs cores confusion: facility notes often list “12 cores” but fail to state “2 targeted lesions.” Lesion count matters; core count does not drive CPT selection.
- Fusion not supported: if fusion is billed but documentation reads like cognitive targeting, expect denial—document the fusion platform/workstation workflow.
- In-bore ambiguity: ensure radiology/facility documentation supports in-bore imaging workflow; vague records invite downcoding/denial.
- Units for additional targeted lesions: the record should support the number of additional lesions (not additional samples).
- Site-of-service mismatch: ensure correct POS/dept indicators (ASC vs HOPD vs clinic) because payer rules differ.
Coverage & policy notes
- Fusion: many payers expect documentation that fusion was performed using a fusion platform/workstation (not cognitive targeting).
- In-bore CT/MRI: “in-bore” should be supported in facility/radiology documentation; confirm payer interpretation during early adoption.
- Prior authorization: some payers require prior auth for MRI-guided pathways—ensure authorization matches performed guidance.
- Recommendation: track denials by payer in early adoption and maintain a short internal payer rules addendum for scheduling/authorization/coding alignment.
Global period awareness (facility perspective)
- 2026 biopsy codes are structured with a 0-day global, reducing confusion about bundled post-op visits related to the biopsy itself.
- Global period does not replace payer coverage rules—documentation still drives payability.
